Table 1. Studies on the prevalence of transfusion transmissible infections in chronically transfusion dependent thalassemia patients.
HBV: hepatitis B virus; HCV: hepatitis C virus; n: number of patients; NR: not reported.
* The positive results calculated prevalence in each study for HBV, HCV, or HIV by any method divided by the total number of thalassemia patients who were tested for that transfusion-related infection.
| Author | Year | Number of patients, n | Prevalence* of HBV n (%) | Prevalence of HCV n (%) | Prevalence of HIV n (%) |
| Rehman et al. [16] | 2011 | 150 | NR | 45 (30%) | NR |
| Ansari et al. [17] | 2012 | 160 | 2 (1.25%) | 21 (13.1%) | 0 (0%) |
| Shahid et al. [19] | 2013 | 150 | 1 (0.66%) | 77 (51.3%) | NR |
| Akram et al. [20] | 2013 | 58 | NR | 22 (37.9%) | NR |
| Nazir et al. [21] | 2014 | 200 | NR | 82 (41%) | |
| Sheikh et al. [22] | 2015 | 145 | 5 (3.5%) | 99 (68.2%) | NR |
| Ali et al. [23] | 2016 | 379 | NR | 123 (32.45%) | NR |
| Kiani et al. [24] | 2016 | 1253 | 38 (3%) | 273 (21.7%) HBV/HCV coinfection: 2 (0.16%) | 6 (0.5%) |
| Sultan et al. [25] | 2016 | 100 | 3 (3%) | 27 (27%) | NR |
| Rashid et al. [26] | 2017 | 130 | 8 (6.2%) | 27 (20.8%) | NR |
| Shah et al. [27] | 2019 | 324 | 6 (1.85%) | 18 (5.56%) | NR |
| Jehan et al. [28] | 2019 | 292 | 3 (1%) | 53 (18.2%) HBV/HCV coinfection: 1% | NR |
| Abid et al. [29] | 2019 | 95 | 2 (2.1%) | 6 (6.31%) | NR |
| Yasmeen et al. [30] | 2019 | 350 | 26 (7.4%) | 103 (29.4%) HBV/HCV coinfection: 21 (6%) | NR |
| Total prevalence | 3786 | 94/2999 = 3.13% | 976/3786 = 26% | NR |